Growing Clinical Biomarker Assays

Abstract

Choosing the optimal time to develop a companion diagnostic alongside therapeutic products can feel like aiming at a moving target. To hit the bull’s eye, one must select the appropriate assay platform for the early validation of predictive biomarkers.

This requirement and several related challenges will be discussed at CHI’s conference on “Clinical Biomarker Assay Development.” Besides taking up the issue of choice of assay platform, presenters will discuss analytical validation strategies, reimbursement requirements, and regulatory compliance issues.

Many pharmaceutical and biotechnology companies employ biomarker analysis for pharmacokinetic/pharmacodynamic (PK/PD) modeling. Often, companies do such evaluation utilizing commercially available assay kits. “The problem is, whether they use home-brewed or commercial kits, groups must be aware of and plan for controlling lot-to-lot kit or assay component variability. This is critical for accurate bioanalysis in support of both preclinical and clinical studies,” says Afshin Safavi, Ph.D., svp of bioanalytical operations and founder, BioAgilytix Labs…

Click for full article

Share This

Other Podcasts

Welcome to episode one of the Molecular Moments podcast! On this first episode, Dr. Chad Briscoe is joined by his guest, Ph.D scientist, Dr. Jim McNally, and they get down to business as the two explore the various nuances in the outstanding work of McNally, how his career in bioanalysis became personal in an unexpected…
In today’s episode, Dr. Chad Briscoe sits down with guest scientist and biomarker expert, Dr. Marianne Fjording (Scientific Officer, BioAgilytix). Marianne and Chad discuss her expertise in biomarkers and EU bioanalysis- including how Denmark became a scientific hub and what fit-for-purpose really means. They also dive into Marianne’s jump from pharma to CRO, a family…